These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34544109)

  • 1. Setmelanotide (Imcivree) for rare genetic forms of obesity.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):e3-e4. PubMed ID: 34544109
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
    Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
    Collet TH; Dubern B; Mokrosinski J; Connors H; Keogh JM; Mendes de Oliveira E; Henning E; Poitou-Bernert C; Oppert JM; Tounian P; Marchelli F; Alili R; Le Beyec J; Pépin D; Lacorte JM; Gottesdiener A; Bounds R; Sharma S; Folster C; Henderson B; O'Rahilly S; Stoner E; Gottesdiener K; Panaro BL; Cone RD; Clément K; Farooqi IS; Van der Ploeg LHT
    Mol Metab; 2017 Oct; 6(10):1321-1329. PubMed ID: 29031731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
    Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects.
    Royalty JE; Konradsen G; Eskerod O; Wulff BS; Hansen BS
    J Clin Pharmacol; 2014 Apr; 54(4):394-404. PubMed ID: 24166760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor.
    Hammad MM; Mohammad A; Alam-Eldin N; Madhu D; Al-Mulla F; Abu-Farha M; Abubaker J
    Life Sci; 2022 Oct; 307():120857. PubMed ID: 35931197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.
    Yeo GSH; Chao DHM; Siegert AM; Koerperich ZM; Ericson MD; Simonds SE; Larson CM; Luquet S; Clarke I; Sharma S; Clément K; Cowley MA; Haskell-Luevano C; Van Der Ploeg L; Adan RAH
    Mol Metab; 2021 Jun; 48():101206. PubMed ID: 33684608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Setmelanotide: First Approval.
    Markham A
    Drugs; 2021 Feb; 81(3):397-403. PubMed ID: 33638809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.
    Kühnen P; Krude H; Biebermann H
    Trends Mol Med; 2019 Feb; 25(2):136-148. PubMed ID: 30642682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MC4R Variants Modulate α-MSH and Setmelanotide Induced Cellular Signaling at Multiple Levels.
    Rodríguez Rondón AV; Welling MS; van den Akker ELT; van Rossum EFC; Boon EMJ; van Haelst MM; Delhanty PJD; Visser JA
    J Clin Endocrinol Metab; 2024 Sep; 109(10):2452-2466. PubMed ID: 38567654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.
    Falls BA; Zhang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1055-1065. PubMed ID: 30048591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.
    Kühnen P; Clément K; Wiegand S; Blankenstein O; Gottesdiener K; Martini LL; Mai K; Blume-Peytavi U; Grüters A; Krude H
    N Engl J Med; 2016 Jul; 375(3):240-6. PubMed ID: 27468060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling.
    Israeli H; Degtjarik O; Fierro F; Chunilal V; Gill AK; Roth NJ; Botta J; Prabahar V; Peleg Y; Chan LF; Ben-Zvi D; McCormick PJ; Niv MY; Shalev-Benami M
    Science; 2021 May; 372(6544):808-814. PubMed ID: 33858992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues.
    Conde-Frieboes K; Thøgersen H; Lau JF; Sensfuss U; Hansen TK; Christensen L; Spetzler J; Olsen HB; Nilsson C; Raun K; Dahl K; Hansen BS; Wulff BS
    J Med Chem; 2012 Mar; 55(5):1969-77. PubMed ID: 22335602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist.
    Bischof JM; Van Der Ploeg LH; Colmers WF; Wevrick R
    Br J Pharmacol; 2016 Sep; 173(17):2614-21. PubMed ID: 27339818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity.
    Nargund RP; Strack AM; Fong TM
    J Med Chem; 2006 Jul; 49(14):4035-43. PubMed ID: 16821763
    [No Abstract]   [Full Text] [Related]  

  • 17. Diabetes: long-acting insulin analogues--are benefits worth the cost?
    Nathan DM
    Nat Rev Endocrinol; 2012 Dec; 8(12):699-700. PubMed ID: 23147577
    [No Abstract]   [Full Text] [Related]  

  • 18. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals.
    Chen KY; Muniyappa R; Abel BS; Mullins KP; Staker P; Brychta RJ; Zhao X; Ring M; Psota TL; Cone RD; Panaro BL; Gottesdiener KM; Van der Ploeg LH; Reitman ML; Skarulis MC
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1639-45. PubMed ID: 25675384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial.
    Roth CL; Scimia C; Shoemaker AH; Gottschalk M; Miller J; Yuan G; Malhotra S; Abuzzahab MJ
    Lancet Diabetes Endocrinol; 2024 Jun; 12(6):380-389. PubMed ID: 38697184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of setmelanotide, an MC4R agonist, for obesity in individuals with Smith-Magenis syndrome.
    Lazareva J; Sisley SR; Brady SM; Smith ACM; Elsea SH; Pomeroy JJ; Roth CL; Sprague JE; Wabitsch M; Garrison J; Yanovski JA
    Obes Res Clin Pract; 2024; 18(4):301-307. PubMed ID: 38987029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.